Search

Contributor:

David S. Boyer, MD

AAO 2021 Late Breakers: DAVIO and NORSE-2

The Multifactorial Pathophysiology of DME

The Multifactorial Pathophysiology of DME

David Boyer MD

Update on Encapsulated Cell Technology

Update on Encapsulated Cell Technology

David Boyer MD, Jonathan L. Prenner, MD

OCT-A May Provide Better Visualizations of Vascularized PED's in AMD patients than FA

OCT-A May Provide Better Visualizations of Vascularized PED's in AMD patients than FA

David Boyer, MD

OCT-A for Identifying CNV in Patients with Type 1 AMD and Assessing Response to anti-VEGF treatment

OCT-A for Identifying CNV in Patients with Type 1 AMD and Assessing Response to anti-VEGF treatment

David Boyer, MD

OCT-A in Context: Why OCT-A Must Be Evaluated Together With OCT B-Scan

OCT-A in Context: Why OCT-A Must Be Evaluated Together With OCT B-Scan

David Boyer, MD

Take-Home Points for APL-2

Take-Home Points for APL-2

David S. Boyer, MD

DEL MAR: Phase 2, Stage 2

DEL MAR: Phase 2, Stage 2

David S. Boyer, MD

An Update on Suprachoroidal RGX-314

An Update on Suprachoroidal RGX-314

David S. Boyer, MD

Central Serous Retinopathy Pearls

Central Serous Retinopathy Pearls

David S. Boyer, MD

An Investigator’s Perspective on the DIAMOND Stage 1 Trial results

An Investigator’s Perspective on the DIAMOND Stage 1 Trial results

David S. Boyer, MD

Safety and Efficacy Results from LIGHTSITE III Trial for Dry AMD

Safety and Efficacy Results from LIGHTSITE III Trial for Dry AMD

David S. Boyer, MD; and Marion R. Munk, MD, PhD

OCS-01 Eye Drops, A Potentially Transformative Treatment Option for DME

OCS-01 Eye Drops, A Potentially Transformative Treatment Option for DME

Ramin Tadayoni, MD, PhD; Arshad M. Khanani, MD; David S. Boyer, MD

AAO 2021 Late Breakers: DAVIO and NORSE-2

David Boyer, MD; and Firas Rahhal, MD